Core Viewpoint - Innovation Medical (002173) reported a closing price of 17.6 yuan on August 8, 2025, with a slight increase of 0.74% and a trading volume of 1.7244 million hands, resulting in a transaction amount of 3.255 billion yuan [1] Group 1: Financial Performance - The company's main revenue for the first half of 2025 was 402 million yuan, a year-on-year decrease of 1.6% [3] - The net profit attributable to shareholders was -11.3613 million yuan, an increase of 29.12% year-on-year [3] - The second quarter of 2025 saw a single-quarter main revenue of 208 million yuan, a year-on-year increase of 0.73% [3] - The gross profit margin was reported at 12.06%, significantly lower than the industry average of 34.93% [3] Group 2: Market Activity - On August 8, 2025, the net outflow of main funds was 165 million yuan, accounting for 5.06% of the total transaction amount [1][2] - Retail investors showed a net inflow of 216 million yuan, representing 6.63% of the total transaction amount on the same day [1][2] - Over the past five days, the stock experienced fluctuations in fund flows, with notable changes in both main and retail investor activities [2] Group 3: Industry Comparison - The total market value of Innovation Medical is 7.767 billion yuan, compared to the industry average of 19.375 billion yuan, ranking 19th out of 42 in the industry [3] - The company has a negative price-to-earnings ratio of -341.8, while the industry average is 23.61 [3] - The return on equity (ROE) stands at -0.64%, significantly below the industry average of 1.24% [3]

创新医疗2025半年报 ...

Core Viewpoint - Innovation Medical reported a slight decline in revenue but a reduction in losses for the first half of 2025, indicating some operational improvements despite challenges [2] Financial Performance - The company achieved a revenue of 402 million yuan in the first half of 2025, representing a year-on-year decrease of 1.6% [2] - The net profit attributable to the company was -11.36 million yuan, showing a reduction in losses compared to the previous year [2] Revenue Sources - The primary sources of revenue and profit for the company are derived from medical services [2] - The improvement in financial performance was attributed to an increase in medical insurance reimbursements and a decrease in credit impairment losses compared to the same period last year [2]

Market Overview - On August 8, the total trading volume of the Shanghai and Shenzhen stock markets was 1.71 trillion yuan, a decrease of 115.3 billion yuan compared to the previous trading day [1] - Sectors that saw significant gains included Xinjiang, rail transit equipment, wind power equipment, and gas, while sectors such as AI, semiconductors, and internet e-commerce experienced declines [1] Top Gainers - Notable stocks with significant gains included: - Guojijinggong (国机精工) with a rise of 9.99% [2] - Huaguang Huaneng (华光环能) up by 10.02% [2] - Rihai Intelligent (日海智能) increased by 10.00% [2] - Hongtong Gas (洪通燃气) rose by 10.03% [2] - Other notable mentions include Liangxin Co. (良信股份) and Jishi Media (吉视传媒) with gains of 9.96% and 10.20% respectively [2] Trading Dynamics - The top three net purchases on the trading leaderboard were: - Shanhe Intelligent (山河智能) with a net purchase of 3.30 billion yuan [5] - Chutianlong (楚天龙) with 2.70 billion yuan [5] - Deen Precision (德恩精工) with 1.34 billion yuan [5] - The top three net sales were: - Kailaiying (凯莱英) with 1.80 billion yuan [6] - Yonyou Network (用友网络) with 1.72 billion yuan [6] - Beiwai Technology (北纬科技) with 1.43 billion yuan [6] Sector Performance - High-performing stocks included: - Guojijinggong (国机精工) with a trading volume of 39.46 billion yuan and a turnover rate of 24.77% [20] - Shanhe Intelligent (山河智能) with a trading volume of 46.39 billion yuan and a turnover rate of 26.26% [20] - Conversely, stocks like Dingjie Smart (鼎捷数智) saw a significant decline of 15.99% with a trading volume of 30.01 billion yuan [20] Institutional Activity - Institutional net purchases were led by: - Guojijinggong (国机精工) with 1.58 billion yuan [7] - Shanhe Intelligent (山河智能) with 1.57 billion yuan [26] - The top net sales by institutions included: - Yingweike (英维克) with 1.95 billion yuan [8] - Kailaiying (凯莱英) with 1.88 billion yuan [8] Notable Stocks and Their Concepts - Shanhe Intelligent (山河智能) is associated with the Yaxia hydropower concept and shield tunneling machines [22] - Chutianlong (楚天龙) focuses on social security cards, digital currency, and cross-border payments [13] - Deen Precision (德恩精工) is involved in robotics, military, commercial aerospace, and AI applications [20]

Group 1 - The stock price of Innovation Medical reached 17.60 yuan as of August 8, 2025, reflecting a 0.74% increase from the previous trading day [1] - The company operates four medical institutions: Jianhua Hospital, Kanghua Hospital, Futian Hospital, and Mingzhu Hospital, with Jianhua Hospital being a tertiary comprehensive hospital [1] - The half-year report disclosed on August 8 shows a revenue of 402 million yuan, a year-on-year decrease of 1.60%, while the net profit attributable to shareholders was a loss of 11.36 million yuan, an improvement from a loss of 16.03 million yuan in the same period last year [1] Group 2 - In the second quarter, the company achieved a net profit of 2.58 million yuan, successfully turning a profit [1] - On August 8, the net outflow of main funds was 165 million yuan, accounting for 2.25% of the circulating market value, while the cumulative net inflow over the past five trading days was 264 million yuan, representing 3.61% of the circulating market value [1]

Core Viewpoint - Innovation Medical reported a decline in revenue and a net loss for the first half of the year, indicating ongoing financial challenges [2] Financial Performance - The company achieved operating revenue of 402 million yuan in the first half of the year, a year-on-year decrease of 1.60% [2] - The net profit attributable to shareholders was a loss of 11.36 million yuan, an improvement from a loss of 16.03 million yuan in the same period last year [2] - Basic earnings per share were reported at -0.03 yuan [2]

创新医疗管理股份有限公司 2025 年半年度 非经营性资金占用及其他关联资金往来情况汇总表 法定代表人：陈海军 主管会计工作负责人：杨建荣 会计机构负责人（会计主管人员）：杨建荣 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 | 上市公司核算 | 2025 年期初占用 | | 2025 年半年度占用累计 | | 2025 年半年度占用 | 2025 | 年半年度偿 | 2025 年半年度期 | | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 的会计科目 | 资金余额 | | 发生金额（不含利息） | | 资金的利息(如有) | 还累计发生金额 | | 末占用资金余额 | | 原因 | | | 控股股东、实际控制人及 | | | | | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | | | | | 小计 | | | | | | | | | | ...

创新医疗管理股份有限公司 2025 年半年度财务报告 创新医疗管理股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 2025 年 8 月 1 创新医疗管理股份有限公司 2025 年半年度财务报告 财务报告 编制单位：创新医疗管理股份有限公司 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 249,045,212.83 | 137,984,131.56 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 213,134,328.80 | 287,799,259.39 | | 衍生金融资产 | | | | 应收票据 | | | | 应收账款 | 74,886,592.50 | 124,184,225.79 | | 应收款项融资 | | | | 预付款项 | 4,227,450.08 | 4,649,527.59 | | 应收保费 | | | | 应收分保账款 | | ...

格隆汇8月8日丨创新医疗(002173.SZ)公布2025年半年度报告，上半年公司实现营业收入4.02亿元，同比 下降1.60%；归属于上市公司股东的净利润-1136.13万元；归属于上市公司股东的扣除非经常性损益的 净利润-1288.41万元；基本每股收益-0.03元。 ...

创新医疗管理股份有限公司 2025 年半年度报告全文 创新医疗管理股份有限公司 2025 年半年度报告 2025 年 8 月 1 创新医疗管理股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责 任。 公司负责人陈海军、主管会计工作负责人杨建荣及会计机构负责人(会计 主管人员)杨建荣声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 请投资者注意投资风险。 本公司请投资者认真阅读本报告，公司在本报告"管理层讨论与分析"中 "公司面临的风险和应对措施"部分，描述了公司未来经营可能面临的主要风 险，敬请广大投资者注意风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第一节 重要提示、目录和释义 | | 2 | | --- | --- | --- | | 第二节 公司简介和主要财务指标 | | 6 | | 第三节 ...